## Lars Aagaard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11391627/publications.pdf Version: 2024-02-01



LADS AACAADD

#	Article	IF	CITATIONS
1	Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis. Molecular Therapy, 2022, 30, 164-174.	3.7	12
2	VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy. Molecular Therapy - Nucleic Acids, 2022, 28, 58-76.	2.3	6
3	Simple Autofluorescence-Restrictive Sorting of eGFP+ RPE Cells Allows Reliable Assessment of Targeted Retinal Gene Therapy. Frontiers in Drug Delivery, 2022, 2, .	0.4	2
4	Methylation silencing and reactivation of exogenous genes in lentivirus-mediated transgenic mice. Transgenic Research, 2021, 30, 63-76.	1.3	3
5	Variants in the <scp>ethylmalonyl oA</scp> decarboxylase ( <scp> <i>ECHDC1</i></scp> ) gene: a novel player in ethylmalonic aciduria?. Journal of Inherited Metabolic Disease, 2021, 44, 1215-1225.	1.7	4
6	Efficient Knockdown and Lack of Passenger Strand Activity by Dicer-Independent shRNAs Expressed from Pol II-Driven MicroRNA Scaffolds. Molecular Therapy - Nucleic Acids, 2019, 14, 318-328.	2.3	13
7	Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy. Molecular Therapy - Nucleic Acids, 2019, 16, 38-50.	2.3	47
8	Enhanced Tailored MicroRNA Sponge Activity of RNA Pol II-Transcribed TuD Hairpins Relative to Ectopically Expressed ciRS7-Derived circRNAs. Molecular Therapy - Nucleic Acids, 2018, 13, 365-375.	2.3	10
9	Improved Lentiviral Gene Delivery to Mouse Liver by Hydrodynamic Vector Injection through Tail Vein. Molecular Therapy - Nucleic Acids, 2018, 12, 672-683.	2.3	22
10	Induced pluripotent stem cells derived from a patient with autosomal dominant familial neurohypophyseal diabetes insipidus caused by a variant in the AVP gene. Stem Cell Research, 2017, 19, 37-42.	0.3	2
11	Improved microRNA suppression by WPRE-linked tough decoy microRNA sponges. Rna, 2017, 23, 1247-1258.	1.6	11
12	Suppression of Choroidal Neovascularization in Mice by Subretinal Delivery of Multigenic Lentiviral Vectors Encoding Anti-Angiogenic MicroRNAs. Human Gene Therapy Methods, 2017, 28, 222-233.	2.1	20
13	Suppression of choroidal neovascularization in mice by subretinal delivery of multigenic lentiviral vectors encoding anti-angiogenic microRNAs. Human Gene Therapy Methods, 2017, , .	2.1	1
14	Mitochondrial Spare Respiratory Capacity Is Negatively Correlated with Nuclear Reprogramming Efficiency. Stem Cells and Development, 2017, 26, 166-176.	1.1	21
15	Enhanced genome editing in mammalian cells with a modified dual-fluorescent surrogate system. Cellular and Molecular Life Sciences, 2016, 73, 2543-2563.	2.4	39
16	Partial correction of the dwarf phenotype by non-viral transfer of the growth hormone gene in mice: Treatment age is critical. Growth Hormone and IGF Research, 2016, 26, 1-7.	0.5	5
17	Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14064.	1.8	43
18	Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity. Stem Cell Research and Therapy, 2015, 6, 144.	2.4	93

Lars Aagaard

#	Article	IF	CITATIONS
19	Molecular mechanisms in DM1 — a focus on foci. Nucleic Acids Research, 2015, 43, 2433-2441.	6.5	75
20	A Novel Homologous Model for Gene Therapy of Dwarfism by Non-Viral Transfer of the Mouse Growth Hormone Gene into Immunocompetent Dwarf Mice. Current Gene Therapy, 2014, 14, 44-51.	0.9	10
21	DDX6 regulates sequestered nuclear CUG-expanded DMPK-mRNA in dystrophia myotonica type 1. Nucleic Acids Research, 2014, 42, 7186-7200.	6.5	45
22	Silencing of endogenous envelope genes in human choriocarcinoma cells shows that envPb1 is involved in heterotypic cell fusions. Journal of General Virology, 2012, 93, 1696-1699.	1.3	10
23	Adenoâ€associated virusâ€delivered polycistronic microRNAâ€clusters for knockdown of vascular endothelial growth factor <i>in vivo</i> . Journal of Gene Medicine, 2012, 14, 328-338.	1.4	40
24	Rational Design of Micro-RNA-like Bifunctional siRNAs Targeting HIV and the HIV Coreceptor CCR5. Molecular Therapy, 2010, 18, 796-802.	3.7	14
25	Gene conversion and purifying selection of a placenta-specific ERV-V envelope gene during simian evolution. BMC Evolutionary Biology, 2008, 8, 266.	3.2	31
26	A Facile Lentiviral Vector System for Expression of Doxycycline-Inducible shRNAs: Knockdown of the Pre-miRNA Processing Enzyme Drosha. Molecular Therapy, 2007, 15, 938-945.	3.7	46
27	Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Research, 2007, 35, 5154-5164.	6.5	249
28	Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Research, 2007, 35, 2333-2342.	6.5	308
29	RNAi therapeutics: Principles, prospects and challenges. Advanced Drug Delivery Reviews, 2007, 59, 75-86.	6.6	780
30	The â^1⁄430-million-year-old ERVPb1 envelope gene is evolutionarily conserved among hominoids and Old World monkeys. Genomics, 2005, 86, 685-691.	1.3	16
31	Efficient replication of full-length murine leukemia viruses modified at the dimer initiation site regions. Virology, 2004, 318, 360-370.	1.1	15
32	Identification of endogenous retroviral reading frames in the human genome. Retrovirology, 2004, 1, 32.	0.9	148
33	Fv1-like restriction of N-tropic replication-competent murine leukaemia viruses in mCAT-1-expressing human cells. Journal of General Virology, 2002, 83, 439-442.	1.3	10